Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and
Frankfurt: “6BX”) (the “
Company”
or “
Relevium”), and its’
wholly-owned subsidiary,
Biocannabix Health Corporation
(the “
BCX”), a company focused on
Paediatric and Geriatric applications of Cannabinoid nutraceutical
and medical food formulations, is delighted to announce that it has
entered in a Letter of Intent (the “
LOI”) with
IAM Health GmbH (the “
IAM”), a
German based Research & Development company, to pursue a number
of pre-defined research opportunities.
The terms of the LOI will allow Biocannabix to
hold a 51% equity interest of the combined research entity and will
continue operations under the IAM Health GmbH name, which will
become the Company’s brand and driver for clinical and research
therapeutics.
IAM HEALTH GmbH PARTNERSHIP
IAM Health GmbH was founded by a group of
multi-disciplinary professionals, combining legal expertise,
medical doctors, research and clinical development specialists, and
contract manufacturing, to focus on the development of new
treatments for autoimmune conditions, including the study of the
role of certain cannabinoids, primarily for the development of
therapies for pediatric applications.
A NEW DIRECTION FOR BIOCANNABIX WITH A
FOCUS ON RESEARCH AND DEVELOPMENT
The partnership between BCX and IAM was designed
to provide continuity to the research the company began in the
pediatric cannabinoid space and will leverage the clinical and
research capabilities both in Germany and Colombia through its
investment in Lifeline Pharma for Nutraceutical and Pharmaceutical
development
Aurelio Useche, CEO of Relevium stated: “We are
extremely pleased to enter into this valued partnership with IAM
Health and their team, as we set a new direction for Biocannabix.
The partnership in Germany will drive focus and solidify the
company’s new direction for the development of proprietary consumer
and medical products”.
Ms. Nina Wlodarczyk, Managing Director of IAM
Health, commented: “We have developed the ideal ecosystem for
conducting research and clinical activities that can leverage not
only our new infrastructure here in Germany, but also the existing
established relationships in Colombia. We are very pleased to join
forces with Biocannabix and have great expectations for the current
year”.
About Relevium
TechnologiesRelevium is a publicly traded Company that
operates in the health and wellness industry, including
cannabinoids, with a primary focus on online distribution. The
principal business of the Company is the identification,
evaluation, acquisition and operation of brands and businesses in
the health and wellness markets and cannabinoids. The Company
pursues its business strategy through an acquisition and
partnership model in a holistic approach to encompass a wide range
of health and wellness consumer products. Relevium operates in
various segments including health, wellness, cannabinoid research
and PPE business.
About IAM HEALTH GmbHBased in
Germany, IAM Health GmbH is a privately owned clinical and research
company in the domains of nutraceuticals, and pharmaceuticals
seeking for partnerships for the development of innovative,
patented nature sourced products.
Neither the
TSX Venture
Exchange nor its
Regulation Services Provider
(as that term
is defined in
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
Cautionary Note Regarding
Forward-Looking StatementsThis release includes certain
statements and information that may constitute forward-looking
information within the meaning of applicable Canadian securities
laws. All statements in this news release, other than statements of
historical facts, including statements regarding future estimates,
plans, objectives, assumptions or expectations of future
performance, including the timing and completion of the proposed
acquisitions, are forward-looking statements and contain
forward-looking information. Generally, forward- looking statements
and information can be identified by the use of forward-looking
terminology such as "intends" or "anticipates", or variations of
such words and phrases or statements that certain actions, events
or results "may", "could", "should", "would" or "occur".
Forward-looking statements are based on certain material
assumptions and analysis made by the Company and the opinions and
estimates of management as of the date of this press release,
including the assumptions that the Company will be able to apply
for and ultimately obtain an ACMPR licence, the proposed business
of Biocannabix will develop as anticipated, that the Company will
raise sufficient funds to develop the Biocannabix business, and
that the Company will obtain all requisite regulatory
approvals.
These forward-looking statements are subject to
known and unknown risks, uncertainties and other factors that may
cause the actual results, level of activity, performance or
achievements of the Company to be materially different from those
expressed or implied by such forward-looking statements or
forward-looking information. Important factors that may cause
actual results to vary, include, without limitation, the risk that
the proposed business developments may not occur as planned; the
timing and receipt of requisite approvals and failure to raise
sufficient funds.
Although management of the Company has attempted
to identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward- looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
outlook that are incorporated by reference herein, except in
accordance with applicable securities laws. We seek safe
harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES
INC.
Aurelio UsechePresident and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INCEmail:
investors@releviumcorp.comWebsite: www.releviumtechnologies.comLike
us on FacebookFollow us on TwitterFollow us on LinkedIn
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jul 2023 to Jul 2024